Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.33 |
| ▸ | LIPC | P11150 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | LSS | P48449 | 1/20 | 0.31 |
| ▸ | GBA1 | P04062 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25479442 | 0.93 | LSS (0.34) | LIPGLIPCHSD17B10LSSGBA1 | |
| SCHEMBL24379948 | 0.84 | HSD17B10 (0.32) | LIPGLIPCHSD17B10LSSGBA1 | |
| SCHEMBL21106934 | 0.84 | CHRNB2 (0.34) | LIPGLIPCHSD17B10LSSGBA1 | |
| SCHEMBL25122639 | 0.83 | PIK3CD (0.37) | LIPG | |
| SCHEMBL25883099 | 0.82 | HRH2 (0.38) | LIPGLIPC | |
| SCHEMBL25730022 | 0.79 | REN (0.36) | LIPGLIPC | |
| SCHEMBL25922657 | 0.79 | REN (0.36) | LIPGLIPC | |
| SCHEMBL24672696 | 0.77 | PIK3CD (0.41) | HSD17B10LSSGBA1 | |
| SCHEMBL23560455 | 0.76 | CHRNB2 (0.37) | HSD17B10LSSGBA1 | |
| SCHEMBL23568087 | 0.76 | ITGB3 (0.36) | HSD17B10LSSGBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| US-20220356185-A1 | MERTK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-11-10 | — | — | US | disclosed |
| US-20220340570-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220340570-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | LIPG 2233/4885LIPC 2617/4885HSD17B10 2107/4885 |
| US-20220356185-A1 | MERTK DEGRADERS AND USES THEREOF | MERTK, ITK, CRKL | LIPG 2088/4885LIPC 2492/4885HSD17B10 1154/4885 |
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | LIPG 2233/4885LIPC 2617/4885HSD17B10 2107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.